StockNews.com Begins Coverage on Enzo Biochem (NYSE:ENZ)

StockNews.com began coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Monday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of ENZ opened at $0.58 on Monday. Enzo Biochem has a 12 month low of $0.56 and a 12 month high of $1.40. The stock has a fifty day moving average price of $0.77 and a 200 day moving average price of $1.00.

Enzo Biochem (NYSE:ENZ) last released its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Institutional Trading of Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. Geode Capital Management LLC grew its stake in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 3.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 368,646 shares of the medical research company’s stock after buying an additional 11,742 shares during the quarter. Geode Capital Management LLC owned about 0.71% of Enzo Biochem worth $413,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.